focus -WSS

focus

author：leisure time 2025-10-01 23:05:00 - browse：9

Blood samples — Marion Berard/AFP/GettyImages

With the advent of disease-modifying Alzheimer’s drugs, everyone in the world of Alzheimer’s diagnostics is bracing for the crush.

Based on their ability to slow cognitive decline, the Eisai/Biogen drug Leqembi won full approval from the FDA this month, and donanemab by Eli Lilly could be approved by year end. Clinicians now have to decide which patients are most suitable for treatment, which means better Alzheimer’s tests need to be developed.

“There’s going to be capacity issues because there’s just not enough neurologists in the world to treat this pool of patients with Alzheimer’s disease at the moment,” said Mark Stearman, a senior international product manager at Roche focusing on Alzheimer’s diagnostics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Raw milk easy to obtain despite bird flu warning, FDA interstate ban

focus

WSS

General Catalyst, Summa Health deal will turn on physician buy

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

Supreme Court to hear if Covid misinformation is protected speech

As H5N1 spreads in cows, experts warn against drinking raw milk

A $475,000 price tag for a new cancer drug: crazy or meh?

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

explore

focus

knowledge

The cancer drug shortage isn’t new — and neither are the solutions

WuXi Biologics execs register to lobby as Congress comes for the company

Supreme Court strikes down use of affirmative action

Cherokee Nation medical school graduates its first class

Walensky prepares to leave CDC — and Congress — behind

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

As demand for Covid shots wanes, Moderna seeks its next success

Novo Nordisk to expand supply of Wegovy for U.S. patients

Trump demands the U.S. pay no more for drugs than other countries … again

Do digital therapeutics have a future in medicine?

knowledge

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

FDA drug safety: Singulair case shows systemic surveillance flaws

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Vertex non

Vertex non

Wikipedia

focus

focus

leisure time